Tango Therapeutics, Inc. (TNGX) Stock Grade

About Tango Therapeutics, Inc.'s fundamentals

Tango Therapeutics is a biotech company with a market capitalization of $4.0 billion that is experiencing strong revenue expansion, with year-over-year growth of 48.3%. However, the company is not yet profitable, reporting a net loss in its latest annual statement and operating at a net margin of -162.9%, indicating that expenses significantly exceed revenues. The company does not pay a dividend and is at a stage typical of early-stage biotechnology firms that prioritize research and development spending over near-term profitability.